Clene's Amyotrophic Lateral Sclerosis Candidate Delays Disease Progression, New Data Shows

Clene Inc CLNN announced new results from exploratory analyses, including delayed time to key clinical progression events in amyotrophic lateral sclerosis (ALS) patients treated with CNM-Au8 in the HEALEY ALS Platform Trial over the 6-months.
ALS is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing a loss of muscle control.
ALS is often called Lou Gehrig's disease, after the baseball player diagnosed with it.
Related: Clene's Lead Amyotrophic Lateral Sclerosis Shows Improved Function, Slowed Disease Progression.
Analyses of prespecified exploratory endpoints from the HEALEY ALS Platform Trial suggest that treatment with CNM-Au8 delayed time to ALS clinical worsening events across all domains, including the need for assisted breathing and placement of stomach feeding tubes.
A 74% decreased risk (lower hazard) of the composite endpoint of time to ALS clinical worsening, which included the first instance of death, tracheostomy, initiation of permanent assisted ventilation, or placement of a feeding tube.
Treatment with CNM-Au8 was also associated with statistically significant and directional trends across all prespecified time to clinical worsening event analyses.
- 98% decreased risk (lower hazard) of death or permanently assisted ventilation.
- 95% decreased risk of death.
- 74% decreased risk of feeding tube placement.
- 63% decreased risk of assisted ventilation.
- 84% decreased risk of ALS-related hospitalization.
- 69% decreased risk of all-cause hospitalization.
Price Action: CLNN shares are up 6.22% at $1.38 during the market session on the last check Thursday.

Market News and Data brought to you by Benzinga APIs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments